ScoreWhy is Anika Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -9.52% of over the last 5 years
2
With a growth in Net Sales of 10.12%, the company declared Very Positive results in Jun 26
- ROCE(HY) Highest at -2.19%
- RAW MATERIAL COST(Y) Fallen by -28.56% (YoY)
- NET SALES(Q) Highest at USD 32.61 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 144.36%, its profits have fallen by -13%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 144.36% in the last 1 year, much higher than market (S&P 500) returns of 22.36%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Anika Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Anika Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Anika Therapeutics, Inc.
144.36%
-0.40
53.91%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-2.86%
EBIT Growth (5y)
-9.52%
EBIT to Interest (avg)
-21.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.71
Tax Ratio
18.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.33
EV to EBIT
-12.30
EV to EBITDA
-25.94
EV to Capital Employed
1.54
EV to Sales
1.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.55%
ROE (Latest)
-6.96%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
ROCE(HY)
Highest at -2.19%
RAW MATERIAL COST(Y)
Fallen by -28.56% (YoY
NET SALES(Q)
Highest at USD 32.61 MM
OPERATING PROFIT(Q)
Highest at USD 4.46 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.67 %
PRE-TAX PROFIT(Q)
Highest at USD 3.38 MM
NET PROFIT(Q)
Highest at USD 3.31 MM
EPS(Q)
Highest at USD 0.24
-6What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD 5.98 MM
CASH AND EQV(HY)
Lowest at USD 79.43 MM
DEBT-EQUITY RATIO
(HY)
Highest at -9.59 %
Here's what is working for Anika Therapeutics, Inc.
Pre-Tax Profit
At USD 3.38 MM has Grown at 231.79%
over average net sales of the previous four periods of USD -2.56 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 3.31 MM has Grown at 219.49%
over average net sales of the previous four periods of USD -2.77 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 32.61 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 4.46 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 13.67 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 3.38 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 3.31 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.24
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -28.56% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 1.5 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Anika Therapeutics, Inc.
Operating Cash Flow
Lowest at USD 5.98 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 79.43 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -9.59 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
